Promising results shown for kidney cancer drug

Feb 04, 2010

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

"Advanced remains a challenging disease, but the outlook for patients has improved in the past year - including the addition of pazopanib, which targets multiple pathways within ," study author Dr. Cora N. Sternberg, chief of the medical oncology department at the San Camillo and Forlanini Hospital in Rome, Italy, said in a news release from the American Society of Clinical Oncology.

Dr. Sternberg also serves as the director of the scientific advisory board for the Columbus Cancer Foundation, a international nonprofit organization devoted to supporting basic cancer research.

Pazopanib inhibits the development of blood vessels that tumors need to grow and spread.

"These clinical findings are indeed very encouraging," said Dr. Antonio Giordano, M.D., Ph.D., the founder and director of the Sbarro Health Research Organization located at Temple University in Philadelphia, PA. "We will look forward to the further studies which are currently evaluating the impact of pazopanib on the overall survival of treated patients."

In a phase 3 study, 233 patients with previously untreated locally advanced or metastastic and 202 other patients with kidney cancer who had been previously treated with interleukin or interferon, were randomly assigned to receive the oral drug pazopanib or a placebo.

Results showed that the time it took for a patient's disease to progress was more than double for the group receiving pazopanib (9.2 months), compared with the placebo group (4.2 months). The most dramatic effect was seen in previously untreated patients (11.1 months for the pazopanib group vs. 2.8 for the placebo) and persisted among those previously treated (7.4 vs. 4.2 months, respectively). The study is ongoing to determine how the drug impacts overall survival.

Common side effects of pazopanib included diarrhea (52 percent), hypertension (40 percent), hair color changes (38 percent), nausea (26 percent), weight loss (22 percent) and vomiting (21 percent).

Explore further: Researcher to cancer: 'Resistance will be futile'

Provided by Sbarro Health Research Organization

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Investigational drug shows promise in ovarian cancer

Sep 15, 2008

An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to a presentation at the 33rd Congress of the European Society for Medical ...

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Recommended for you

Researcher to cancer: 'Resistance will be futile'

3 hours ago

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease. "Cancer cells rapidly ...

How does prostate cancer form?

5 hours ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

11 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.